Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of NIS793 with and without spartalizumab in combination with gemcitabine and nab-paclitaxel compared to gemcitabine and nab-paclitaxel alone in patients with untreated metastatic pancreatic cancer.

General Information

NCT#: NCT04390763
Study ID: CNIS793B12201
Trial Phase: Phase II

Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Spartalizumab, NIS793

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search